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Abstract approved:
The pharmacokinetics of a novel acetaminophen sustained release
suspension (ASRS), were evaluated in children and adults. ASRS consists of
sustained release acetaminophen beads (3 mm diameter) dispersed in a grape
jelly. Beads were coated with a multi-laminar sandwich, polymeric, release rate
controlling sandwich membrane. Saliva samples were collected for 24 hours,
post-dosing, and acetaminophen concentration determined using HPLC. In 10
adults administered a dose of 30 mg/kg ASRS, mean pharmacokinetic
parameters are Tp= 2.8 hours, Cmax= 12.0 ug/ml and MRT (infinity)= 7.7 hours,
indicating, by comparison to immediate release, that sustained release of
acetaminophen from the suspension is obtained in vivo. A similar study was
conducted in 12 healthy children, age 2 through 11 years. In 9 children (75%),
mean saliva concentrations reach a peak value of 5ug/ml at 4 hours and then
decline to 2.5 ug/ml at 12 hours. In 3 children, mean peak saliva concentrations
of 10 ug/ml occur at 1 hour and then decline at a rate expected following
administration of immediate release acetaminophen. It is believed that
incomplete sustained release effect was obtained in these 3 children because the
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INTRODUCTION
Acetaminophen is a safe and effective drug that is widely used to reduce
fever and pain. Following administration of a conventional oral tablet,
acetaminophen is absorbed rapidly and completely with peak blood
concentrations occurring within 1 hour. After 1 hour, acetaminophen blood
concentrations decline rapidly with a half-life of 1.5-3.0 hours. Because analgesia
and antipyresis are correlated with blood concentrations, acetaminophen must be
dosed every 4-6 hours to maintain fever and pain reduction. The frequency of
dose administration may be reduced if absorption of acetaminophen from the
gastrointestinal tract takes place over a longer period of time compared to
immediate release. One method of extending the time of acetaminophen
absorption is to reduce the rate at which acetaminophen leaves the dosage form
and becomes available for absorption from the lumen of the gastrointestinaltract.
Polymers have been widely used by the pharmaceutical industry to
reduce the rate at which drugs leave a dosage form. The strategy employed
herein is to apply a coating of polymers to acetaminophen beads. Releaserate of
acetaminophen from coated beads is reduced by the polymer coating since the
diffusion paths through the membrane are tortuous and of limited number
compared to the paths that are available to an uncoated bead surfaceexposed to
solution. The release rate from beads can be controlled by polymer selectionand
thickness of the polymer coating applied. Temperatureat which polymers are
applied and the addition of excipients may also influence the releaserate by2
changing the number of diffusion paths. Other factors may also be considered in
the formulation of a sustained release dosage form.
According to accepted dosing protocols, 700 mg of acetaminophen is
required every four hours to maintain effective control of feveror pain in a 70 kg
man. If frequency of administration is reduced to a single dose every 12 hours
then the dose required would be 2100 mg. Formulation ofa solid oral dosage
form containing 2100 mg of active drug would be impossible formany people to
swallow, thus sustained release acetaminophen must be formulatedas small
multiple solid doses or in a form that is easy to swallow in large amounts. A
suspension was selected for formulation of acetaminophen sustained release
since suspensions are easy to swallow. Suspensions are also ideal for
administration to children since children frequently are unable to swallow large
tablets.
Chapter 1 of the thesis describes the manufacture and in vitro
characterization, by in vitro dissolution, of 6 experimental sustained release
acetaminophen suspension formulations. Based on the in vitro dissolution
results, one formulation was identified as having release rate characteristics that
may provide sustained therapeutic blood concentrations of acetaminophen for a
period of 12 hours. 10 healthy adults were administered 30 mg/kg of the
formulation. The results show that mean concentrations of acetaminophenare
greater then 2 ug/ml for a 12 hour period post dosing, suggesting that the
formulation, when dosed at 30 mg/kg, may bean effective anti-pyretic in adults.
In chapter 2, 30 mg/kg of the formulationwas administered to 10 febrile
(1010C-1040C) children. The results presented in chapter2 show that the mean
reduction in fever was significantly greater than the fever reduction thatis
expected if no acetaminophen was given. Ina separate experiment the
pharmacokinetics of the dosage form, using thesame methods as in chapter 1,3
was evaluated in 10 healthy children administered 30 mg/kg of the formulation.
Pharmacokinetic evaluation in children shows thatmean concentrations of
acetaminophen in saliva, in children, are greater than 2 ug/ml during the 12 hour
period post dosing, confirming that the dosage form is expectedto be an effective
antipyretic.
In chapter 3, a correlation relationship between in vitro dissolution and in
vivo absorption of KC1 sustained release is developed and usedto simulate in vivo
responses that are expected following the administration of KCL formulations
that differ with respect to in vitro dissolution profiles. The analysis performedin
chapter 3 is useful as a "model" approach to correlating in vitro dissolutionresults
with in vivo drug absorption.4
CHAPTER I
DEVELOPMENT OF SUSTAINED RELEASE ACETAMINOPHEN
SUSPENSION
ABSTRACT
This research describes the formulation and evaluation ofa sustained
release suspension that is stable with respect to release rate of drug in vitro,
during significant periods of storage in a hydrating suspension medium. The
dosage form consists of acetaminophen loaded beads (3mm) coated with three
layers of coating polymers ("sandwich coating"). Coated beadsare suspended in
a low pH, high viscosity, commercial grape jelly. The in vitro release rate of
acetaminophen from the sustained release suspension stabilized afteran
equilibration period of 15 days of refrigerated storage of the coated beads in the
suspension medium. A candidate formulation that demonstrated in vitro
dissolution rates consistent with the objective of providing sustained therapeutic
concentrations in vivo was evaluated in 10 healthy adults. Pharmacokinetic
evaluation of acetaminophen concentrations in salivaover a period of 24 hours
post dosing demonstrate high relative bioavailability from the dosage form and
peak concentration occuring about 2 hours later than fora comparable dose of
immediate release formulation of acetaminophen. Deconvolution of the
observed in vivo saliva concentration data reveals that the sustained release
suspension releases acetaminophen much more rapidly then predicted by in vitro
dissolution. The data demonstrate that sustained therapeutic concentrations of
acetaminophen were maintained at effective concentrations for periods ofat least
12 hours following administration of a single dose of acetaminophensustained
release suspension.5
INTRODUCTION
Many drugs must be dosed frequently, in relatively large amounts to
maintain a desired therapeutic effect. Compliance with regimens requiring
frequent drug administration is often poor, especially when the patient is
responsible for timely drug administration. Compliance is also undermined if
the dosage form is difficult to swallow or if the experience with the dosage form
is stressful and unpleasant (a bitter drug taste). Compliance is improved, and
therapeutic objectives are more readily met, if the dosage formulation is easy and
convenient to administer. Unfortunately, many drugs are commercially available
only as an immediate release tablet or capsule which requires frequent drug
administration, thus the best dosage form for a given patient may not always be
available. The diversity of dosage forms (or lack of diversity) available for a drug
reflects the demands of the patient population for which the drug is intended
and problems inherent in the formulation of alternative dosage forms.
Many drugs are potent, have long half-lives, and are used primarily in
patient populations that do not have significant problems swallowing small
tablets or capsules. However, sustained release formulations of relatively low
potency drugs may be large and difficult to swallow. Thus, benefits of sustained
release may be outweighed by problems associated with large solid formulations.
The size limitation inherent in solid sustained release formulations may be
overcome if sustained release can be provided in a non-solid formulation that is
readily swallowed in larger volume. Sustained release suspensions may provide
the compliance benefits of sustained release while providing the ease of
swallowing associated with oral suspensions.
Despite the significant therapeutic advantage of sustained release
suspensions over conventional immediate release formulations, a comprehensive6
sustained release suspension formulation strategy, applicable to many drugs, has
not been widely available. This research describes the formulation and
evaluation of a sustained release suspension that is stable with respect to release
rate of drug in vitro, during significant periods of storage in a hydrating
suspension medium. The dosage form evaluated herein consists of
acetaminophen coated beads surrounded by three layers of polymers ("sandwich
style") commonly used in the formulation of conventional oral sustained release
products. The beads are suspended in a high viscosity, commercial grape jelly.
The sustained release suspension described herein has the following
characteristics: 1) Release rate stability during storage, 2) Use of FDA approved
coating polymers, 3) Use of familiar polymer application technology, i.e. spray
coating, 4) Taste masking of unpalatable drugs, 5) Release rate may be
controlled by varying the amount of rate controlling polymers applied.
Acetaminophen was chosen as a challenging model drug since it has a
short half life (1.5-3.0 hours), and has a relatively low potency (10-15 mg/kg for
symptomatic relief of fever and pain). In addition the concentration of
acetaminophen in the central compartment may be determined non-invasively
from saliva. Formulation of acetaminophen sustained release suspension may
provide substantial therapeutic benefits to children and the elderly, populations
which frequently have problems swallowing large solid oral dosage forms.7
MATERIAL AND METHODS
Production of acetaminophen beads
150 grams of non-parriel sugar beads (28-30 Mesh) were coated with 450
grams of USP grade acetaminophen (Mallincrodt Inc., St. Louis, MO.) dissolved
in 700 ml 95% ethanol USP. Polyvinylpyrrolidinone (2% w/w), MW 40,000 and
hydroxypropylcellulose (2% w/w) were added to the alcoholic solution as
binders. The application of acetaminophen ethanolic solution required 2 hours at
ambient temperature (-25° C). After application of ethanolic acetaminophen
solution, drug coated beads were allowed to dry for 20 minutes at 500 C in order
to remove residual ethanol. Beads were removed from the fluid bed and
weighed and assayed to evaluate the total amount of drug loaded per total
weight of beads. Acetaminophen content was expected to be 70% of total bead
weight, and beads were approximately 3 mm in diameter.
Production of the sustained release suspension
Polymer film coating technology was used to produce controlled release
(sustained-action) acetaminophen.The coating apparatus consisted of a spray-
coating chamber, with a 7 inch Wurster column (STREA-1, Aeromatic Inc.,
Columbia, MD) mounted on a fluid-bed dryer (Lab-Line/P.R.L. Hi-Speed Fluid-
Bed Dryer, Lab-Line Instruments, Inc., Melrose Park, IL). Ethyl cellulOse
(Aquacoat ®, Type ECD-30, Lot J7211, FMC Corp., Philadelphia, PA., USA) and
Eudragit® L30D, Lot #12-906-1280, Rhom Pharma GMBH, FRG were used as the
coating materials. Two plasticizers were used: triethyl citrate ( Triethyl citrate
99%, Aldrich Chemical Co., Milwaukee, WI.) and dibuty sebecate (Dibutyl
Pthalate 99%, Mallinckrodt, Inc., St. Louis, Mo.). Three separate applications of
polymers were made during the manufacturing process. Loading of polymers
was calculated as weight percent of polymer solids, including plasticizers, per8
unit weight of acetaminophen beads. The order and amount of application was
varied, but in one example was 2% Aquacoat® (Ethyl Cellulose suspension), 4%
Eudragit® L3OD (Methacrylic acid copolymer, Type A), 2% Aquacoat. Polymer
solutions were applied rapidly and then coated beads were allowed to dry in the
fluid bed dryer for 30 minutes before the next application of polymer solution.
All processes were undertaken at 70° C. The commercial polymer suspensions
(30% solids weight) were diluted with an equal volume of de-ionized water
before use. Triethyl citrate (TEC), 15% of total solids, and dibutyl phtalate (DBP),
15% of total solids, were added as plasticizers. Coated beads were then
dispersed in a commercial fruit jelly (Danish Orchards Grape Spread®, Lot #0D3
9 Al, Vendelbo Konserves A/S, Denmark, 53 grams of beads plus 47 grams of
jelly) and refrigerated until use. During dosing the suspension was dispensed
precisely by volume with a syringe. The suspension contained 37%
acetaminophen by weight.
In vitro dissolution
In vitro release rate of acetaminophen was determined using the paddle
method (USP XXI) at 100 rpm and 370C. Approximately 100 mg of
acetaminophen sustained release suspension was weighed and placed in 900 ml
of enzyme free, simulated gastric fluid, pH 1.4 for the first 2 hours of dissolution.
At 2 hours gastric fluid was decanted, and poured through a filter paper in order
to collect non-dissolved material including sustained release beads. For hours 2
through 24, beads were exposed to enzyme free, simulated intestinal fluid, pH
7.4, equilibrated to 370C. Double distilled, deionized water was used to prepare
all dissolution media. 5 ml samples of dissolution media were collected, with
replacement, over a period of 24 hours and analyzed spectrophotometrically for
acetaminophen at 254 nm using a Beckman UV 34 spectrophotometer. No9
detectable interference from jelly or excipients used in the manufacture of the
sustained release suspension was observed.
Analysis of acetaminophen in saliva by HPLC
Concentrations of acetaminophen in saliva have been correlated in a 1 to 1
fashion to plasma concentrations (1).The HPLC assay method for
acetaminophen is similar that has been reported previously (2). Since the
principle metabolites of acetaminophen, acetaminophen gluronide and
acetaminophen sulphate, elute much earlier then acetaminophen, the
quantitation method is specific for acetaminophen. Saliva samples were
collected in plastic vials and frozen at -20° C prior to assay. An aliquot of saliva
was centrifuged at 14,000 rpm for 2 minutes to pelletize particulates. 50 ul of
supernatant was transferred to a micro-centrifuge tube containing 100 ul water
with internal standard (2-acetamidophenol, Sigma Chemical, St. Louis, MO.) and
vortexed for 30 seconds. 50 ul of the mixture was injected onto an HPLC system
with a 300 mm length C-18 column (Microsorb-MV, Rainen, Woburn, MA.) with
>20,000 theoretical plates. A autosampler (WISP Model 712, Waters Associates
Inc., Milford, MA.) was used for all injections. A mobile phase of 20% methanol
80% water was used. Elution volumes of acetaminophen and the internal
standard 2-acetamidophenol were 7.5 ml at 15.0 ml respectively. Analytes were
detected with a fixed wavelength UV detector at 254 nm (Model 440, Waters
Associates Inc., Milford, MA.). A integrator (Model C-R3a, Schimadzu, Japan)
was used to calculate peak areas. Standard curves were prepared by spiking 1
ml of saliva with 50 ul of acetaminophen solutions. The range of standard
concentrations was 0.25 ug-30 ug/ml. Coefficients of determination were greater
then >0.995 on all days. All saliva samples were frozen at -20C prior to assay.10
Patient enrollment
Protocols and informed consents for the pharmacokinetic study were
approved by the Investigational Review Board, Oregon Health Sciences
University (OHSU), Portland, OR. An investigational new drug (IND)
application was filed with FDA and approved. Adults were recruited from
health care providers and students at OHSU in February, 1993.
Pharmacokinetic study
10 healthy adults age 26-38 were recruited. Signed, informed written
consent was obtained from each subject before the study began. Subjects were
provided with a single oral dose of the sustained release suspension (30 mg/kg
acetaminophen) to take at home, along with plastic vials for the collection of
saliva samples. Subjects were instructed not to chew the sustained release beads.
No restrictions were placed on food prior to or during the study with the
exception that subjects were instructed not to eat or drink for 5 minutes prior to
collection of a saliva sample. Saliva samples were collected prior to dosing and
at various times during a 24 hour period.
Statistical methods
Procedure NUN of SAS (Statistical Software, Cary, NC) was used to
estimate Weibull parameters (3) associated with in vitro dissolution profiles.
Cumulative absorption of acetaminophen from the sustained release suspension
over time was determined with an analytical deconvolution algorithm
PCDCON.11
RESULTS AND DISCUSSION
Figure 1 shows in vitro release rate profiles of acetaminophen sustained
release suspension formulations that differ with respect to amount of coating
polymers applied. Figure 1 shows that very little, if any acetaminophen has been
released or is "free" in the suspension medium since the acetaminophen released,
at 15 minutes is less then 3% for all sustained release suspension formulations.
This result is surprising since a large acetaminophen concentration difference is
present between the bead interior and the suspension medium. The absence of
acetaminophen in the surrounding dissolution medium results in sustained
release acetaminophen suspensions which lack the bitter taste that is associated
with conventional oral solutions. Mansell (4,5)and Sahjwalla (6) have previously
observed that sandwich style sustained release acetaminophen beads, stored in
low pH, low osmotic pressure aqueous medium will release acetaminophen into
the surrounding medium. If the amount of acetaminophen present is sufficiently
large, the solubility limit for acetaminophen in the medium will be rapidly
attained. Since the interior of beads stored in jelly is 'wet' in appearance, lack of
water for dissolution of acetaminophen in the bead interior cannot explain these
results. Absence of acetaminophen in the suspension medium reported herein
may arise from the high osmotic pressure of the suspending medium used in the
formulation. Earlier results with the jelly vehicle and similar sadwich coated
acetaminophen beads were also effective at masking the bitter taste (4).
Figure 1 also shows that release rate decreases as the total amount of
controlled release polymers increases.Mansell (4) has previously reported
similar release patterns for triple layer acetaminophen suspension, however the
total amounts of polymers required by to produce in vitro release patterns
comparable to those reported herein were approximately twice as great. SinceFigure I.1
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In vitro percent release acetaminophen from sustained release acetaminophensuspension
formulations that vary in amounts of coating polymers applied. The coatingsare ethyl
cellulose/methyl methacrylate/ ethyl cellulose. Solidsquare 2/2/1, open square 2/2/4, solid circle 3/5/2,
open circle 3/5/4, solid triangle 3/5/6, open triangle 3/5/8. All formulations stored 3 days under
refrigerated conditions (5 0C) prior to dissolution.13
all formulation parameters used herein, with the exception oftemperature at
which polymer solutions are applied (400C Mansell, 700C here),are identical to
those used previously, differences in in vitro release rate pattern fora given
amount of polymer applied must arise from an application temperature
dependent effect on the permeability of the polymeric rate controlling
membrane. Hossain (7) reports similar application temperature dependent, in
vitro release rate behavior for acetaminophen beads coated with mono-layers of
ethyl cellulose (Aquacoat® ). Using scanning electron microscopy, Hossain
observed that as application temperatures increase, film coalescence becomes
more complete and as a result, fewer pores are visible on the surface of the ethyl
cellulose, rate controlling membrane. These results suggest that the in vitro
dissolution behavior of acetaminophen beads, coated with either singleor
multiple layers, are similarly effected by temperature of polymer suspension
application and total amount of polymers applied. The effect of totalamount of
coating polymers applied on in vitro release rate from sandwich style
acetaminophen sustained release suspensions (applicationat 70 CO), is
summarized in figure 2.
Figure 2 shows the log linear relationship between time to 63.2% release
and coating level. Time to 63.2% releasewas estimated by non-linear estimation
of parameter i of the Weibull function (3) associated with eachin vitro
dissolution release pattern.
Weibull function Ft= F.1elZ,
Parameters [3 (curvature parameter) and 'rwere estimated simultaneously, while
F infinity (percent released at time infinity)was constrained to 100 percent ofFigure 1.2
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Time to 63.2% release of acetaminophenvs coating level (weight percent polymeric coating solids).
Open circles time to 63.2% released basedon non-linear estimation of Weibull parameter b for various
acetaminophen sustained release suspension formulations.15
acetaminophen present in the suspension. [3 andt were estimated with the SAS
statistical package. The Weibull model is non-mechanistic and hasbeen used
previously to evaluate the complex in vitro release pattern from sustainedrelease
formulations (3). Differences between observed percent released and
mathematically estimated percent releasedwere within 2 % for all formulations
at all times with the exception of the 3/5/2 formulation whose bi-phasic release
pattern was not adequately described by the Weibull function. The degree of
correlation between total amount of polymer applied and timeto 63.2% release
(correlation coefficient =0.93) indicates that the relationshipmay be used to
predict in vitro dissolution rate characteristics ofmany formulations of this type
within the range described by trial formulations. However, thebi-phasic pattern
of the 3/5/2 formulation whichmay be due to rupture of the outer coat
(discussed below) indicates there are limitingcases where the relationship in
figure 2 does not apply. More sophisticated predictive modelsusing the
curvature parameter 13 may be developed. Predictive models basedon a
relatively small descriptive set of trial formulations and applicationof
convolution methods may enable the rapid identification offormulations with
precisely defined pharmacokinetic characteristics.
The in vitro dissolution behavior ofsome sandwich style, acetaminophen
sustained release suspension formulations arises from thespecific interaction of
dissimilar polymers (ethyl cellulose and methyl methacrylate)present in the
release rate controlling membrane. Thus, unusual invitro dissolution patterns
may be produced with the sandwich style coating strategy.
The 3/5/2 (solid circles in figure 1) showsa distinct bi-phasic release
pattern. During exposure to simulated gastric fluid, pH 1.4, forthe first 2 hours
of in vitro dissolution, the 3/5/2 releases acetaminophenat a slightly greater rate
then 3/5/4, 3/5/6 and 3/5/8 formulations. Thisslightly greater release rate,16
during the first 2 hours, compared to 3/5/4, 3/5/6 and 3/5/8 formulations is
consistent with the expectation that larger amounts of applied polymers will
produce consistently slower release rates in vitro. However, when the 3/5/2
formulation is exposed to simulated intestinal fluid, pH 7.4, the rate of
acetaminophen release increases dramatically and greatly exceeds the rate that is
predicted by extrapolation of change in release rates of 3/5/8, 3/5/6 and 3/5/4
formulations. In fact, the rate of acetaminophen release from the 3/5/2
formulation from 2 through 12 hours is closer too, though still less then, the
release rate observed for 2/2/1 and 2/2/4 formulations. The rapidrate of
acetaminophen release from the 3/5/2 formulation, followingexposure to
simulated intestinal fluid, suggests that swelling of the middle layer of methyl
methacrylate in response to pH 7.4, drastically changes the permeability of the
release rate controlling membrane. Mansell (5) observed that the addition ofan
exterior layer of methyl methacrylate had no effecton the release rate pattern
from mono-layer ethyl cellulose formulations in simulated intestinal fluid, pH
7.4. This result indicates that an exterior coating of methyl methacrylate when
applied to ethyl cellulose, dissolves very rapidly at pH 7.4 and makesno
contribution to the reduction in rate of drug release in vitro. Mansell also showed
that if the amount of methly methacrylate is 3 fold greater then theamount of
ethyl cellulose present in the exterior layer,a rapid and complete loss of both
middle and exterior layers will occur followingexposure to intestinal fluid, with
the result that both coats will have a negligible effecton reduction of in vitro
release rate. Since the release rate of acetaminophen from the 3/5/2formulation
is significantly less then either the 2/2/1or 2/2/4 formulation, it is likely that
complete loss of both the middle and exterior layer didnot occur. The
observation that a complex release rate patternmay be produced by a
homogeneous sandwich coat formulation (i.e. nota mixture of several different17
controlled release parts, example enteric coated plus sustainedrelease) may be
useful in optimizing some drug therapies.
Changes in in vitro acetaminophen release patterns for the 2/2/4
formulation were assessed over a 65 day period of refrigeratedstorage (50 C) to
determine if this formulation would be suitable for evaluationin vivo. Since
enrollment of patients in clinical efficacy and pharmacokineticstudies may occur
over a period of 1 to 2 months, a candidate formulation for in vivo evaluation
must demonstrate a high degree of release rate stability followingstorage.
Figure 3 shows that release rate from the 2/2/4 sustained releasesuspension
decreases slightly during the period of 3 to 15 daysstorage but that release rate
pattern changes little during 15 through 65 days storage. Sahajwalla (6) found
that significant change in in vitro releaserate pattern of multi-laminar, sandwich
style acetaminophen sustained release beads, duringstorage in aqueous
suspension medium, did not occur from 2 weeks through1 year of storage.
Similar rate were obtained by Mansell (5) although forshorter storage time.
Thus, it is likely that the sustained release acetaminophensuspension that is
described herein will be stable for periods much longer than65 days. Chemical
stability of acetaminophen in the sustained release suspensionwas not evaluated
here but has been shown to be high inaqueous solution (8). No detectable levels
of p-aminophenol, the major hydrolysis productof acetaminophen were detected
by HPLC.
The 2/2/4 formulation was selected for in vivoevaluation in humans since
the formulation produces in vitro releaserate patterns that are consistent with the
objective of providing sustained therapeuticconcentrations of acetaminophen in
blood for a period of 12 hours followinga single dose (9), is release rate stable
and has a pleasant, non-bitter taste that is readilyacceptable.Figure 1.3
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Effect of refrigerated storage (50C) on in vitro release rate from 2/2/4 (ethyl cellulose/methyl
methacrylate/ methyl cellulose) acetaminophen sustained release suspension. Solidsquares 3 days
storage, open circles 15 days storage, open squares 65 days storage.
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The 2/2/4 formulation was evaluated in 10 healthy adults (ages 26-37, 1
Female, 9 Males) dosed at 30 mg/kg. Figure 4 shows the individual and mean
saliva concentrations of acetaminophen in these adults over a 24 hour period.
The lowest concentration at 12 hours was 2 ug/ml and the mean is 4 ug/ml.
Hossain (10) has suggested that 2 ug/ml will be effective to reduce fever and that
5 ug/m1 will be analgesic; thus the sustained release acetaminophen suspension
may be an effective antipyretic for periods of 12 hours post administration.
Individual profiles are consistent with sustained release of acetaminophen from
the dosage form. Table 1 shows individual and mean non-compartmental
pharmacokinetic parameters. Mean MRT (24 hours) of 6.4 hours for adults dosed
with sustained release suspension of acetaminophen is longer then the 4.1 hours
reported for healthy adults following administration of a 1000 mg dose of
immediate release acetaminophen tablets (1). This comparison indicates that
sustained release of drug is provided by the suspension. Mean time to peak
concentration also occurs later for sustained release suspension (2.8 hours) than
for immediate release (1000 mg dose, Cmax= 0.8 hours).
A rigorous estimate of relative bioavailability of the sustained release
suspension could not be made since neither an intravenous nor an immediate
release formulation were administered. Across study pharmacokinetic
comparisons must be viewed with caution, but may be useful in certaincases
where a drug has previously been well characterized. Thus,a comparison to
literature values for AUC reported for adults following administration of
immediate release formulations of acetaminophenmay be useful, since inter-
study variation in reported pharmacokinetic parameters for adults is relatively
small (1). Such comparisons assume a 1:1 relationship between saliva and
plasma drug concentrations, which has been shown to exist,on average, for
acetaminophen. Following the administration of 16 mg/kg of acetaminophenasFigure 1.4
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Individual subjects acetaminophen in saliva profiles following administration of2/2/4 acetaminophen
sustained release suspension. Mean concentration of acetaminophen solidsquares. Error bars indicate
SEM (of mean) at each time point.Table I.1Non-compartmental pharmacokinetic parameters of adults.
Subject 1 2 3 4 5 6 7 8 9 10 Average
(SEM)
Tp(hours) 2.0 3.0 4.0 4.0 4.0 4.0 1.0 2.0 2.0 2.0 2.8 (1.1)
Cmax (ug/ml) 11.7 8.4 12.5 8.5 15.2 10.0 11.513.3 14.814.4 12.0 (2.5)
AUC 24 + (ug *hr /ml)144.378.3116.491.5129.885.1120.696.5154.8 113.0 (26.9)
AUC 12 (ug *hr /ml) 91.1 58.2 86.260.3103.868.784.9 79.6107.6108.684.9 (18.5)
AUC infinity
(ug *hr /ml)
162.180.8119.995.2137.889.3125.399.0159.1 118.7 (29.9)
MRT 24 (hours) 10.3 4.1 6.4 5.4 7.0 4.4 6.6 4.4 8.6 6.4 (2.1)
MRT 12 (hours) 5.5 5.3 5.7 5.5 5.3 5.1 5.2 4.9 5.5 5.6 5.4 (0.3)
MRT infinity *
(hours)
9.2 7.4 7.7 8.2 7.4 7.1 7.7 6.5 7.8 7.7 (0.8)
24 hour saliva concentration for subject #10 unavailable, AUC 24 hours, AUC infinity, MRT24 hours and MRT
infinity not calculated.
+ AUC infinity calculated as AUC infinity= AUC 24 hours+ C(24 hours)/Kel, where Kel=0.267, where AUC 24 hours
is calculated by trapazoidal rule.
24 hours
[ft * C(t) +(C(24 hours)
* /
/Kel(1+ Kel)
MRT infinity = o hours
AUC infinity
where the integral is approximated using the trapazoidal rule and Kel=0.267.22
a immediate release formulation, Sahajawalla and Ayres (6) report a steady state,
multiple dosing AUC (to infinity) of 58.8 ug*hr/ml. If linearity is assumed (4,6) a
dose of 30 mg/kg will produce an AUC of 110.3 ug*hr/ml. Based on these
assumptions, a relative bioavailability of 106% is estimated for subjects dosed
with 30 mg/kg of the sustained release suspension. This value for mean relative
bioavailability for subjects dosed at 30 mg/kg is a little higher then the 84 and
91% relative bioavailability reported for two acetaminophen sustained release
formulations evaluated in healthy adult males (12) and the value of 90% reported
by Mansell (4). These results all suggest that hepatic and gastrointestinal
biotransformation of acetaminophen prior to systemic delivery are not greatly
increased by decreasing the rate at which acetaminophen is released by a dosage
form, which is consistent with Sahajawalla (6) but different than Bonin (10).
The rate of absorption of systemically available acetaminophen following
administration of the sustained release suspension was evaluated by
deconvolution (13). An elimination rate constant of 0.267 h-1 (6) was used asa
weighing (impulse response) function for all subjects since individual
elimination rate constants could not be estimated from the data due to
administration of a sustained release product. Thus, the deconvolution dataare
not to be viewed as "exact", but rather represent trends, which should be quite
useful, on the average. Figure 5 shows the estimated cumulative percent of
systemically available acetaminophen absorbed over time for the 10 subjects
enrolled in the study. On the average, 60% of bioavailable acetaminophen is
absorbed in a nearly linear fashion for the first 4 hours, with the remaining 40%
being absorbed slowly over the period of 4 through 24 hours.
A comparison of estimated mean percent absorbed in vivo and percent
released in vitro is shown in figure 6. Figure 6 shows that absorption behavior of
the dosage form in adults differs from the behavior predicted by in vitro0
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Figure 1.5In vivo percent bioavailable acetaminophen absorbed determined by deconvolution. Each lines is one
subjects individual absorption rate profile.Figure 1.6
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In vivo percent bioavailable acetaminophen absorbedvs percent acetaminophen released from 2/2/4
sustained release acetaminophen suspension. In vitro dissolution is fora formulation stored 65 days
under refrigerated conditions prior to dissolution:open squares. In vivo percent bioavailable
acetaminophen absorbed, mean of 10 subjects: solid line witherror bars (SEM).25
dissolution. A time scaling approach (14) is sometimes useful, since in vivo
absorption profiles that appear to be different than in vitro dissolution profiles
may become superimposable after this mathematical treatment. Time scaling did
not ameliorate the lack of correspondence between in vivo absorption and in vitro
dissolution. The lack of correlation is attributable to thevery rapid absorption of
acetaminophen that occurs during the period of 0 through 4 hours. It is possible
that in vivo absorption rate observed here was influenced by surfactantsor
enzymes in the gastrointestinal tract which were not employed in the in vitro
dissolution conditions utilized.
Pharmacokinetics and ability to reduce fever of the sustained release
suspension described herein has recently been evaluated in healthy and febrile
children (Manuscript in preparation, Ka lns and Ayres, 1993). In children therate
of absorption following administration of the sustained release suspensionis
much slower, for the first 3 hours, than observed in adults. Relative
bioavailability (inter-study comparisons) of the sustained release suspension in
children was found to be approximately 85%. The sustained release suspension
was found to reduce fever in children for prolonged times, suggesting that the
sustained release suspension will be an effective antipyretic in both childrenand
adults.26
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CHAPTER II
EVALUATION OF ANTIPYRESIS AND PHARMACOKINETICS OF
SUSTAINED RELEASE ACETAMINOPHEN SUSPENSION IN CHILDREN
ABSTRACT
The pharmacokinetics and pharmacodynamics of a novel sustained
release acetaminophen suspension were evaluated in children,age 2
thorough 11 years.The sustained release suspension consists of sandwich
coated acetaminophen beads (3 mm diameter) dispersed ina grape jelly.
Beads are coated with a multi-laminar, polymeric, release rate controlling
membrane. Pharmacokinetics were determined in 12 healthy children
administered a single 30 mg/kg dose of sustained release suspension.Saliva
samples were collected for 24 hours, post-dosing, and acetaminophen
concentrations determined using HPLC. In 9 children, mean saliva
concentrations reach a peak value of 5 ug/ml at 4 hours and then declineto
2.5 ug/ml at 12 hours.Pharmacokinetics of this group are consistent with
sustained release of acetaminophen from the dosage form in vivo, since
acetaminophen concentrations in saliva peak later and declinemore slowly
compared to immediate release (peak at 0.5-1.0 hour, half-life following peak
1.5-3.0 hours). Estimated relative bioavailabillty of the sustained release
suspension is approximately 90%. In 3 children, mean peak saliva
concentrations of 10 ug/ml occur at 1 hour and then decline ata rate similar
to the rate following administration of immediate release acetaminophen. It
is believed that incomplete sustained release effectwas obtained in 3 children
because the sustained release beads were chewed priorto swallowing. In a
separate pharmacodynamic study, body temperature change in 10 febrile (101-28
1040F) children was monitored for 24 hours followingadministration of a
single, 30 mg/kg dose of sustained release acetaminophen suspension. Mean
temperature declined for a period of 12 hours with 20F and 3.30F decrements
observed at 2 and 12 hours respectively. The sustained release suspension
was readily accepted by all children enrolled in the studies. The results
indicate that a single dose of 30 mg/kg sustained release acetaminophen
suspension, given every 12 hours, may be as effective in reducing feveras
three 10 mg/kg doses of immediate release acetaminophen givenevery 4
hours.29
INTRODUCTION
The onset of fever is one of the most frequentreasons that people will
seek medical attention for their children. Theconcern and anxiety that is
associated with fever (1,2) is not misplaced since fever almost alwayshas a
distinct infectious etiology that may require medical intervention.While
fever indicates the presence of an active diseaseprocess, elevated body
temperature is benign (3). Despite the benign nature of elevated body
temperature, parents with febrile children will frequently attemptto reduce
their child's fever with drugs. Pharmacologic interventions specifically
directed towards reducing fever without effecting the underlying infectious
agent may slow resolution of the disease process (4,5) and thusmay be
considered unwarranted (6). However, the clinical goal of resolvingthe
infection must be balanced against the overall improvementin quality of life
that may be achieved by reducing fever. Fever controlmay reduce malaise
and enable the fever suffer to carry out the functions of dailylife i.e.playing,
sleeping. In addition, the rapid and profound reductionin body temperature
possible through the use of antipyretic drugs reduces feveranxiety (1) and
promotes the feeling that a positive, demonstrable intervention is being
made. Since most acute infections will resolve withor without specific
interventions to reduce fever, fever reductioncan be made safely with little
effect on outcome. Because of the perception that feverreduction is beneficial
it is likely that Americans will continueto administer antipyretic drugs to
their children. The selection ofan antipyretic to administer is based on
several criteria.
Antipyretics should be safe, effective, have few sideeffects and be easy
and convenient to dose. Among the drugs thatare widely used to reduce30
fever, acetaminophen has few side effects (7), is extremely safe (8) and
effective when dosed correctly (9). Unfortunately, acetaminophen hasa half
life of approximately 2 hours which requires that doses be administeredevery
4-6 hours to maintain effective plasma concentrations (10). In addition, solid
oral formulations of the drug are relatively large (500mg) andmay be difficult
for some adults to swallow and are inappropriate for children who require
relatively small doses. To address the needs of adults who find swallowing
difficult, and children, the pharmaceutical industry has developed oral
solutions of acetaminophen. Oral solutions may be easier to swallow then
solid oral formulations and may be dosed precisely. However, because of the
intensely bitter taste of acetaminophen, the experience withan oral solution
may be unpleasant and stressful. Oral solutions, like solid dosage forms,
must be administered frequently which may be inconvenient. Formulating
acetaminophen as a sustained release suspensionmay eliminate or
significantly reduce many of the inconvenient and unpleasantaspects of
currently available formulations.
The goal of this research was to evaluate the performance ofa
sustained release acetaminophen suspension in terms of pharmacokinetics,
ability to reduce fever, and apparent ease of administration. Children,age 2-
11 years were selected as a population thatmay benefit from an improvement
in acetaminophen formulation. Results indicate thata single dose of the
sustained release suspension is readily swallowed by children, producessaliva
concentrations of acetaminophen consistent with sustained release ofdrug,
and reduces fever.31
MATERIALS AND METHODS
Production of acetaminophen beads
150 grams of non-parriel sugar beads (28-30 Mesh) were coated with 450
grams of USP grade acetaminophen (Mallinkrodt Inc., St. Louis, MO.) dissolved
in 700 ml 95% ethanol USP. Polyvinylpyrrolidinone, MW 40,000 and
hydroxypropylcellulose were added to the alcoholic solution as binders. The
application of acetaminophen ethanolic solution required 2 hours at ambient
temperature (-25° C). After application of ethanolic acetaminophen solution,
drug coated beads are allowed to dry for 20 minutes at 50° C in order to remove
residual ethanol. Beads were removed from the fluid bed and weighed and
assayed to evaluate the total amount of drug loaded per total weight of beads.
Acetaminophen content was expected to be 70% of total bead weight, and beads
were approximately 3 mm in diameter.
Production of the sustained release suspension
Polymer film coating technology was used to produce controlled release
(sustained-action) acetaminophen.The coating apparatus consisted of a spray-
coating chamber, with a 7 inch Wurster column (STREA-1, Aeromatic Inc.,
Columbia, MD) mounted on a fluid-bed dryer (Lab-Line/P.R.L. Hi-Speed Fluid-
Bed Dryer, Lab-Line Instruments, Inc., Melrose Park, IL). Ethyl cellulose
(Aquacoat®, Type ECD-30, Lot J7211, FMC Corp., Philadelphia, PA., USA) and
Eudragit® L30D, Lot #12-906-1280, Rhom Pharma GMBH, FRG were used as the
coating materials. Two plasticizers were used: triethyl citrate ( triethyl citrate
99%, Aldrich Chemical Co., Milwaukee, WI.) and dibuty sebecate (dibutyl
pthalate 99%, Mallinckrodt, Inc., St. Louis, Mo.). Three separate applications of
polymers were made during the manufacturing process. Loading of polymers
was calculated as weight percent of polymer solids, including plasticizers, per32
unit weight of acetaminophen beads. The order of application was 2%
Aquacoat® (Ethyl Cellulose suspension), 4% Eudragit® L3OD (methacrylic acid
copolymer, Type A), 2% Aquacoat. Polymer solutions were applied rapidly and
then coated beads were allowed to dry in the fluid bed dryer for 30 minutes
before the next application of polymer solution. All processes were undertaken
at 70° C. The commercial polymer suspensions (30% solids weight) were diluted
with an equal volume of de-ionized water before use. Triethyl citrate (TEC), 15%
of total solids, and dibutyl phtalate (DBP), 15% of total solids, were added as
plastacizers. Coated beads were then dispensed in a commercial fruit jelly
(Danish Orchards Grape Spread®, Lot #0D3 9 Al, Vendelbo Konserves A/S,
Denmark, 53 grams of beads plus 47 grams of jelly) and refrigerated until use.
During dosing the suspension was dispensed precisely by volume with a
syringe. The suspension contained 37% acetaminophen by weight.
Analysis of acetaminophen in saliva by HPLC
Concentrations of acetaminophen in saliva have been correlated in a 1 to 1
fashion to plasma concentrations (1). The HPLC assay method for
acetaminophen is similar that has been reported previously (2). Since the
principle metabolites of acetaminophen, acetaminophen gluronide and
acetaminophen sulphate, elute much earlier then acetaminophen, the
quantitation method is specific for acetaminophen. Saliva samples were
collected in plastic vials and frozen at -20° C prior to assay. An aliquot of saliva
was centrifuged at 14,000 rpm for 2 minutes to pelletize particulates. 50u1 of
supernatant was transferred to a micro-centrifuge tube containing 100u1 water
with internal standard (2-acetamidophenol, Sigma Chemical, St. Louis, MO.) and
vortexed for 30 seconds. 50u1 of the mixture is injected onto an HPLC system
with a 300mm length C-18 column (Microsorb-MV, Rainen, Woburn, MA.) with
>20,000 theoretical plates. A autosampler (WISP Model 712, Waters Associates33
Inc., Milford, MA.) was used for all injections. A mobile phase of 20% methanol
80% water was used. Acetaminophen elutes at 7.5 ml and the internal standard
2-acetamidophenol at 15.0 ml. Analytes were detected with a fixed wavelength
UV detector at 254 nm (Model 440, Waters Associates Inc., Milford, MA.). A
integrator (Model C-R3a, Schimadzu, Japan) was used to calculate peak areas.
Standard curves were prepared by spiking 1m1 of saliva with 50u1 of
acetaminophen solutions. The range of standard concentrations was 0.25ug-
3Oug/ml. Coefficient of determination were greater then >0.995 on all days. All
saliva samples were frozen at -20C prior to assay.
Patient enrollment
Protocols and informed consents for the fever response study and
pharmacokinetic study were approved by the Investigational Review Board,
Oregon Health Sciences University, Portland, OR. An investigational new drug
(IND) application was filed with FDA and approved. Children for both studies
were recruited during the period of January and February, 1993.
Fever response study
Children, 2 through 11 years of age with oral temperatures of 101° to 104°
F were recruited from patients who came to the Outpatient pediatric clinic of
Dohrnbecker Children's Hospital, Portland, Oregon. Children who were
concurrently taking drugs whose metabolism may be effected by the
acetaminophen (phenytoin, phenobarbital, etc.), or had a reported history of
antipyretic drug use within the 2 hours prior to presentation in the clinic, or had
a medical history of hepatitis or other liver disease, or reported a previous
adverse experience with acetaminophen were excluded. The study was described
by a pharmacist both verbally and in writing. Signed, informed written consent
was obtained from each subjects parent before the study began. Patients
received a single oral dose of the sustained release suspension (30mg/kg34
acetaminophen) while in the clinic. Parents were instructed regarding the use of
a digital thermometer which was provided, and how temperatures were to be
recorded on a form (also provided). No monetary incentive was offered for
participation in the study. Oral temperatures were recorded prior to dosing with
the suspension and 0.5, 1, 2, 3, 4, 6, 8,12 and 24 hours post dose.
Pharmacokinetic study
Healthy children, ages 2 through 11 were recruited. Signed, informed
written consent was obtained from each subjects parent before the study began.
Parents were provided with a single oral dose of the sustained release suspension
(30mg/kg acetaminophen) to give to their child at home, along with plastic vials
for the collection of saliva samples. All parents and patients were carefully
coached to swallow the dose gently without chewing or crushing the beads in the
jelly. No restrictions were placed on food prior to or during the study with the
exception that parents were instructed not to allow their children to eat or drink
for 5 minutes prior to collection of a saliva sample. Saliva samples were collected
prior to dosing and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing.35
RESULTS AND DISCUSSION
The novel sustained release suspension consists of acetaminophen
loaded beads (3mm) coated with three layers of coating polymers ("sandwich
coating"). Coated beads are suspended ina low pH, high viscosity,
commercial grape jelly. Polymers are applied to acetaminophen beadsin the
order of ethyl cellulose (Aquacoat®, Type ECD-30), methyl methacrylate
(Eudragit® L30D, Methacrylic acid copolymer, Type A), ethylcellulose
(Aquacoat®, Type ECD-30). Triple coated beads suspended in highosmotic
pressure jellies have been previously been shown to have a high degree of in
vitro release rate stabilty during periods ofup to 1 year storage (13). Because
of the relatively low pH and high osmoticpresure of the suspending jelly,
very little water flux accross the release rate controlling membranesoccurs
and as a consequence, detectable amounts of acetaminophenare not found in
the jelly. This means that the bitter taste of acetaminophenis masked. In
addition, unique bi-phasic in vitro dissolution patternsare described by some
triple layer formulations.
Depending on the relative amounts of methyl methacrylate andthe
exterior coat of ethyl cellulose, some triple coat formulationshave been
observed to release acetaminophen slowly at low pH, andupon exposure to
high pH, release drug at a muchmore rapid rate. However the rate of rapid
release can be controlled and thuscan be much slower then the "burst"
release that is often evident in enteric coated products.Bi-phasic release
patterns may be desirable for some drug therapies.Bi-phasic release patterns
can also be achieved by the mixing of sustained release particles thatrelease
drug at dissimilar rates. However, mixed formulationssuffer from
manufacturing problems associated with segregationof particles that differ36
with respect to size and surface charge. Since triple coated beadsare relatively
homogeneous,segragation during manufacture is less likely to bea problem
compared to mixed formulations.
Pharmacokinetics of the sustained release formulationwere evaluated
in 10 healthy, Caucasian children dosed with 30mg/kg of acetaminophen
sustained release suspension. The age, weight andsex of these subjects is
found in table 1. Figure 1 shows the concentration of acetaminophenin
saliva over time for individuals. Samples from 6 of 10 children in thisgroup
showed very high saliva concentrations of acetaminophen (30-100 ug/ml)
during the first 0.5 hour of the study. It is likely thatsome children were
unable to swallow the dosage form without chewing and breakingsome of
the sustained release beads incorporated in the jelly which released drug
which may have become trapped in the oral cavity. Residual acetaminophen
attributable to bead breakage was cleared from the oral cavity within thefirst
hour, in an apparent first order process, witha t1/2 of approximately 15
minutes. In these children, 0.25 and 0.5 hour concentrationswere fit to a
mono-exponential decay expression. The expected value of the decay
expression was subtracted from the observed acetaminophen concentrationin
saliva for 0.25, 0.5, 1 and 2 hour. Data obtained after correcting forearly high
values are shown in figure 1 and were used in all subsequentcalculations.
Figure 1 shows that sustained release of drugwas achieved in most
children, and that some children display pharmacokinetics whichare
consistent with some immediate releaseas well. Table 2 shows non-
compartmental pharmacokinetic parameters for the sustainedrelease
acetaminophen suspension in healthy children. Basedon MRT and Cmax for
individuals, a group that absorbed acetaminophen rapidly(n=3) and a group
that absorbed acetaminophen slowly (n=7)were identified. Differences inTable II.1Demographic data of children in pharmacokineticstudy.
subject age wt (kg) sex
6 21.4 F 1
2 4 16.7 M
3 11 42.9 F
4 7 21.4 F
5 9 34.8 M
6 5 20.0 M
7 2 14.8 F
8 10 33.3 M
9 7 26.7 M
10 5 20.5 M14
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Figure IDConcentration of acetaminophen in saliva for subjects in pharmacokinetic study (n=10).
25Table 11.2Non-compartmental pharmacokinetic parameters of sustained release formulation in healthy children.
Subject Tp (hr.) C max
(ug/ml)
AUC
(ug*h/m1)
MRT (hr.)
1 6 5.18 46.09 10.05
2 4 5.16 64.82 10.14
3 6 5.60 79.38 11.24
4 2 6.70 74.80 9.74
6 3 14.00 95.38 6.40
7 3 6.23 81.29 9.69
8 3 6.03 89.61 10.30
9 6 7.27 66.00 9.10
11 2 10.26 47.73 5.54
12 3 11.44 81.55 6.57
Average (SEM) 3.8 (1.6) 7.8 (3.0) 72.7 (16.5) 8.9 (2.0)
AUC and MRT calculated to 24 hours using linear trapezoidal rule. Time to peak (Tp) and Cmax observed values.40
rates of absorption may arise from chewing of beads prior to swallowing.
Difference in MRT and Cmax between these two groupsare statistically
significant (p<.05) in spite of the small sample sizes involved. Of the three
children with early release of drug, 2 showed >2ug /ml of acetaminophen in
saliva 12 hours post dosing, a level greater then expected if all drug in the
dosage form had been released immediately. Thus, even incases in which
significant immediate release occurred, a sustained releasewas in part
preserved, providing a relatively high concentration of acetaminophen for 12
hours. Figure 2 shows the mean acetaminophen concentration in saliva for
the two identifiable subgroups receiving the sustained release product. The
mean drug concentration of the sustained release group shows a gradual
increase to reach a peak concentration of 5.5 ug/ml at 4 hours witha gradual
decline to 3.5 ug/ml at 12 hours. Hossain and Ayres (14) have suggested that
acetaminophen may be expected to provide an anti-febrile effectso long as the
drug concentration exceeds 2ug/ml.
The cumulative amount of acetaminophen input into the systemic
circulation following administration of the sustained release formulationwas
calculated by deconvolution (15) and is shown from timezero to 24 hours for
each individual in figure 3. A mono-exponential impulseresponse function
(weighing function), based on population pharmacokineticparameter
estimates from febrile children dosed with 12.5mg/kg immediate releaseoral
formulation was used (16). A value of 1.03 1-1 and 0.42 h--Iwere used for F/Vd
and Kel respectively.The sustained adsorption group (n=3) exhibita rapid
input for the first hour, followed by a gradual positive input for thefollowing
24 hours, indicating that even in cases wherea large portion of available
acetaminophen was input rapidly, a sustained releasewas still achieved. The
sustained absorption group (n=7) exhibiteda rapid input for the first hour,12
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Figure 11.2Mean concentrations of acetaminophen in saliva following administration of acetaminophen sustained
release in healthy children. Solid circles mean of 3 subjects with early high values (Subjects 6, 11, 12),open
squares mean values of 7 subjects without early high peak values (Subjects 1,2,3,4,7,8,9,11). Error bars SEM
of mean.40
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Figure 11.3Cumulative acetaminophen absorbed from sustained release dosage formin healthy children. Population
pharamcokinetics used as an impulse response function (weighing function).See text.
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followed by a gradual positive input for the following 24 hours, indicating
that even in cases where a large portion of available acetaminophenwas
input rapidly, a sustained release was still achieved. The slow absorption
group (n=7) shows a nearly constant rate of input for the first 6 hours
followed by a gradually decline in input rate with significant input of drug
occurring for at least 12 hours.
Use of deconvolution methods enables a direct comparison between in
vivo absorption rate of bioavailable acetaminophen and release of
acetaminophen from the sustained release suspension in vitro.Individuals
in vivo cumulative absorption was normalized by dividing cumulative
amount absorbed at a given time by the cumulative amount absorbed at 24
hours. This normalization method assumes that all absorption of
bioavailable acetaminophen in vivo is 100% at 24 hours, whichmay not be
entirely accurate but is a close approximation in this case. A comparison
between mean normalized percent released in vivo for children exhibiting
slow rate of acetaminophen input, and percent released in vitro is shown in
figure 4. A very close correlation between release rate in vitro and in vivo
absorption is found for the first 6 hours. After 6 hours the dosage form
appears to release drug at a slower rate in vivo then in vitro.Correlation
was not attempted for the 3 subjects with rapid absorption since it is believed
they crushed some drug beads and correlation is not expected with in vitro
dissolution where crushing was not avoided.
A time scaling approach (17) was applied to refine the correlation
between in vitro release and in vivo absorption. A time scalingparameter
for in vitro dissolution data was calculated by first obtaininga non-linear
estimate of Weibull parameters associated with in vivo absorptionrate:100
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Where 13 and i are parameters estimated by non-linearcurve fitting
procedures and t is time. The resulting fit is within 2% of themean in vivo
percent absorbed at all times.In vitro mean percent dissolution was fit to a
Weibull model using the in vivo parameters estimates for 13 and i with the
addition of an estimated time scaling term a:
F = F.,in vivo
vivo
at
vivo
1e
Tio
The value of a was estimated to be 1.2. Avery similar approach using the
Weibull mathematical model of dissolution and time scaling has been
reported previouslyl8. Figure 5 shows that following introduction ofa time
scaling parameter (a=1.2),in vitro dissolution is within 1% of in vitro
dissolution release percent for all times up to 12 hours. Thevery close
correlation between the time scaled in vitro releaserate and in vivo
absorption rate suggests that an FDA, level A correlation relationshipis
present (19). The improved correlation from application of time scalingmay
simply result from adding one more correction term to the mathematical
relationships employed rather than beingan effect of time. However, these5 10 15
Time (hours)
20 25
Figure 11.5In vitro, in vivo correlation after applyingan in vitro time scaling factor. Solid squares are normalized in
vitro % release with time scaling (factor=1.2); solid line is normalizedin vivo % absorbed.47
findings are still useful since in vivo performance of dosage formsof this
type may be predicted precisely by in vitro dissolution, using the
relationships described.
A rigorous estimate of relative bioavailabilty of the sustained release
suspension could not be made since an intravenousor an immediate release
formulation were not administered. A comparison to literature valuesfor
AUC reported for children following administration of immediaterelease
formulations of acetaminophen may be useful, since inter-studyvariation in
reported pharmacokinetic parameters for children is relatively small (20).
Such comparisons assume a 1:1 relationship between saliva andplasma drug
concentrations, which has been shown to exist,on average, for
acetaminophen. Following the administration of 12.5mg/kg of
acetaminophen as a immediate release formulation, Brownet al. (15) report a
AUC (to infinity) of 35.4 ug*hr/ml. If linearity is assumed (21,22) a dose of 30
mg/kg will produce an AUC of 85.0 ug*hr/ml. A relativebioavailabilty can
be estimated for the sustained release suspension, basedon the preceding
estimate of immediate release AUC, of 85%. This value forrelative
bioavilability is in good agreement with the 84 and 91%relative
bioavailability reported for two acetaminophen sustained release
formulations evaluated in healthy adult males (16),compared to
acetaminophen solution in the same subjects. This wouldindicate that
hepatic and gastrointestinal biotransformation of acetaminophenprior to
systemic delivery are not greatly increased by decreasingthe rate at which
acetaminophen is released by a dosage form, which isconsistent with
Sahajawalla (20) but different then Bonin (21).
The pharmacokinetic investigation of the dosage formin healthy
children confirmed the hypothesis that the sustainedrelease formulation is48
able to produce a sustained concentration of acetaminophen in saliva fora
period of 12 hours, and that the concentrations produced by the dosageform
may effectively control fever. The ability of the dosage form to reduce fever
in children was evaluated in a population of acutely ill childrenage 2
through 11. Demographic data of children enrolled,concurrent drugs and
diagnosis are presented in table 3.
The sustained release suspension was readily accepted by children and
parents. Flavor, texture and appearance were generally acceptedas was the
instruction to swallow without chewing or crushing the beads. Results from
the earlier study suggest that most subjectswere able to comply with these
instructions. Of 12 children enrolled, 1 child immediately vomited the
suspension shortly after administration, andone child refused to take the
dose. Cause of vomiting was not attributed to the suspension,but rather to
the general condition of the patient.
Oral temperatures collected for each subject andmean values at each
observation time are given in table 4.Subjects 1,4,5 and 6 showed a large
effect (>2 Fo) by 1 hour, while subject 7 showed littleresponse to treatment. It
is interesting to note that subjects 1,4 and 6 didnot receive concomitant
antibiotic therapy (Table 3). Other subjects exhibiteda gradual decreasing
fever during the study period. Figure 6 shows oraltemperature for each
patient over the 24 hour period following administration ofthe sustained
release acetaminophen formulation. Mean values given intable 4 show an
overall decreasing trend, however the relatively largevariance associated
with the mean temperature at each time doesnot imply that a statistically
significant reduction in oral temperature is achieved.This result is not
surprising since the response of fever to antipyretic drugsis variable, oral
temperature at time of enrollment varied overa wide range, and the numberTable 11.3Demographic data, diagnosis and concurrent medications of children participatingin fever control study.
subject weight (kg) Diagnosis Concurrent age sex Temp (F0)
Medication
1 4 M 17.2 101 viral none
2 4.5 F 15 101.1 Strep phar. Penicillin
3 3 M 15.2 103.3 Strep phar. Penicillin
4 1.5 M 12 103.5 viral none
5 2 F 11.8 102.2 OM Amoxicillin
6 6 F 18.6 103.9 viral none
7 7 M 50 103.6 Strep Cephelexin
8 7 M 19.1 103 Sinusitis Amoxicillin
9 4 F 15.1 104.9 OM Amoxicillin
10 7 M 33.6 102.7 OM Amoxicillin
Diagnosis codes: viral= general viral syndrome, Strep phar.= Presumed streptococcal pharyngitis(culture results not
known), OM= Otitis Media. Strep= culture positive streptococcal pharyngitis. Subject10 was a treatment failure on
Penicillin VK, hence the use of Cephelexin in treatment. All antibioticswere given orally.Table 11.4Body temperature response to administration of a sustained release suspension of acetaminophen.
Time (hr.) 0 0.5 1 2 3 4 6 8 12 24
Subject
1 101 100.198.6 99 99.599.2100.4100.399.598.7
2 101.1 101 99.9 99.2 99.498.9 99 99 99 99
3 103.3103.2102.2102101.8100.8100.299.599.899.2
4 103.5100.2101.5 102 99.4 99 99 99
5 102.299.198.697.998.6 98.997.998.6
6 103.9103.8100 100 99 100 100 100.198.998.9
7 103.6104102.6103.2103.8104.3102.9102.9101103.8
8 103 102.6102.1101.9102.2 101100.599.1 98.1
9 104.9104.7 104104.2103.4102.7102.5 101.5
10 102.7 102.3 102.3102.9101.399.799.1 99.1
Average102.7102.1100.9100.9101.2101.4100.7100.199.2899.59
SEM 1.2942.0171.6092.1852.1231.891.3531.4540.8881.73106
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Figure 11.6Oral temperature of febrile children administered sustained release acetaminophensuspension.
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of subjects enrolled in this study was small. Oral temperatureat time of
enrollment may be normalized by subtracting the temperature at time of
enrollment from each subsequent oral measurement takenover the 24 hour
study period. The resulting plots of fever reductionover time can be seen in
figure 7. Table 5 shows that mean fever reduction standard deviationat each
time is reduced compared to standard deviation of themean oral temperature
given in table 4. One sided student t-tests of mean fever reduction show that
a statistically significant fever reduction (p<0.05) is achieved at 8, 12 and 24
hours relative to the temperature at time of enrollment. Temperature in
some patients may have decreased even if no treatment had been
administered since the underlying infection may insome individuals be
nearing resolution at time of enrollment, and thusmean fever is expected to
decline without treatment.
Literature reports of temperature reduction in children following the
administration of placebo generally indicates that feverresponse to non-
treatment is negligible. However, Walson et al. (23) report that following
administration of placebo, febrile children showa steady decrease in mean
fever, with a total reduction of 1.1 F in 8 hours. Wilsonet al. (24) report that
placebo did not produce a reduction greater then 0.2 COat any time during a 6
hour study period. Kauffman et al. (25) report that placebo treated children
showed a small increase (<0.5 CO) inmean body temperature over an 8 hour
study period. Attributing the statistically significant fever reductionin this
study to the treatment, to temperaturea time zero is made with caution. It is
concluded that the sustained release suspension formulation hasa helps to
reduce fever in children, a claim thatmay require testing in more patients to
be validated with greater confidence.5 10 15
Time (hours)
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Figure 11.7Fever reduction of febrile children administered sustained release acetaminophen suspension. Solidsquares
are the mean fever reduction.Table 11.5Fever reduction for subjects enrolled in feverresponse study. AUC(12 Hour) and AUC(24
hour) for temperature vs. time curve calculated by lineartrapezoidal rule.
Subject
Time (hours)
1 2 3 4 5 6 7 8 9 10Average (SEM)
0.5 0.90.1 0.13.33.1 0.10.4 0.40.2 0.9 (1.37)
1 2.4 1.2 1.1 2 3.63.9 1 0.9 0.4 1.8 (1.24)
2 2 1.91.3 4.33.9 0.4 1.10.9 2.0 (1.41)
3 1.51.71.5 3.64.9-0.20.80.70.4 1.7 (1.62)
4 1.82.22.51.5 3.9-0.7 2 1.50.2 1.6 (1.38)
6 0.62.1 3.14.1 3.90.72.52.21.4 2.3(1.26)
8 0.72.13.84.53.33.80.73.92.4 3 2.8 (1.33)
12 1.52.13.54.54.3 5 2.6 3.6 3.4 (1.23)
24 2.32.14.14.53.6 5-0.24.93.43.6 3.3 (1.58)
AUC (12 hr.) 15 23 32 36 31 47 8.4 22 16 19 25 (11.5)
AUC (24 hr.) 38 48 78 90 7810723 52 36 63 61 (26.7)55
The febrile response to treatment with acetaminophen immediate
release dosage forms is characterized by dose dependence (19), anti-clockwise
hysteresis. Acetaminophen antipyresis also does not dependon age or
etiology of infection (26,27). Peak reduction in feveroccurs 3-4 hours post
dosing, and 2-3 hours later then the observed peak plasma concentration.
Rate of increase in body temperature following peak reduction is slower then
the initial decline in temperature.
The relationship between saliva concentration and fever reduction in
this study is shown in figure 8. Figure 8 shows that fever reductionoccurs
later (12 hours) then peak saliva concentrations (4 hours) and that rate of
decrease in body temperature is slower in general then thatseen with
immediate release formulations. A 1 to 1 mapping of fever reduction to
acetaminophen concentration in saliva is shown in figure 9.
The anti-clockwise hysteresis described by the mapping of the sustained
release acetaminophen suspension is very similar in shapeto the hysteresis
map, following immediate release acetaminophen (21), described by Hossain
(13). A notable difference is that the loop described in 12 hours bythe
sustained release suspension is described in 3-4 hours by immediate release
formulations. It is quite surprising to note that at the 'end' time of the
hysteresis loops, for immediate release dosage formsa drug concentration of 2
ug/ml is associated with a 1.10 temperature decrease but for thesustained
release suspension, 2ug/m1 is associated with 1.80temperature decrease.
After equilibrium (with a deep tissue compartment), onewould expect the
same effect from equal drug concentrations. Examination of this effect is
underway since it has significant clinical implication if confirmed.However
the finding may simply be due to different subject populationsor study
design.5
Time (hours)
Figure 11.8Mean fever reduction and mean acetaminophen concentration in saliva. Observedtemperature and mean
acetaminophen concentration over time were observed in differentgroups of children. Open circles, mean
acetaminophen concentration in saliva of children who absorb acetaminophen slowly(n=9), closedsquares
mean fever reduction (n=10).ug/ml Acetaminophen
Figure 11.9Comparison of hysteresis of sustained release suspension (solid squares) and immediate release(Walson, et
al., 1989). Arrows indicate time course of transit. Peak acetaminophenoccurs at 1 hour and 4 hours for
immediate and sustained release respectively. Time end points 8 and 24 hours for immediate and sustained
release respectively.58
Several explanations for the hysterisis loop of antipyresis have been
offered. The pharmacologic action of acetaminophen is to reduce synthesis of
PGE2 a prime mediator of thermoregulation (28). Since the primaryorgan of
thermoregulation is the hypothalamus, a rate limiting step in antipyresismay
be the rate at which effective concentrations of drug developat this site (29).
In support of this model is the observation that acetaminophen timecourse
in cerebrospinal fluid (CSF) suggests a course similar to analgesic effect (30).
This means that a map of acetaminophen concentration in CSFvs analgesia
would show no looping, but rather a straight line. Since analgesia and
antipyresis show a similar time course relative to acetaminophen
concentration in blood, antipyresis hysterisismay also collapse if a CSF
concentration map is constructed. The model assumes that the
hypothalamus is in equilibrium with CSF with respect to acetaminophen,
and further that CSF-tissue partitioning is the most importantroute of
acetaminophen entry to hypothalamic tissue. These assumptionsare as yet
unproven. Wu et al. (31) have recently observed that acetaminophen inhibits
transcription of prostaglandin synthase at clinically relevantconcentrations
in human umbilical endothelial tissue culture. If acetaminophenacts in a
similar manner in hypothalamic tissue, then the antipyresishysterisis is a
result of lag times associated with catabolism of mRNA codingfor the
prostaglandin synthase and clearance of expressedenzyme from the
hypothalamus. Half lives of mRNA coding for prostaglandinsynthase have
been reported to be less then 10 minutes ina variety of different rat tissues
(32). In an earlier report, Wu et al. (33)report that the degradation kinetics of
prostaglandin synthase in whole human umbilical endothelialcells are
biphasic, with a rapid degradation half life of 10-20 minutesfollowed by a
much slower elimination half life of 2 hours. Therelatively slow increase in59
body temperature following peak antipyresis is explained by a lag time
required for sufficient quantities of enzyme to be expressed. Our results do
not support the validity of one model over another, however our results do
suggest that the time to reach peak temperature reduction may be effected by
the rate at which acetaminophen is absorbed. This may be somewhat
unexpected based on immediate release dosage forms as one might expecta
slower input to have no influence on peak effect time as drug distribution
could be as fast with slow input as with fast input, i.e. distribution should be
able to occur as rapidly as slow absorption even if distribution is slower then
rapid absorption.
The sustained release formulation evaluated here-in in a fever model
may also be an effective long acting analgesic. Acetaminophen sustained
release formulations have been evaluated in several different pain models.
Nielsen et al. (34) report that a single dose of sustained release acetaminophen
produces a significant and prolonged analgesia, in a laser pain model, fora
period of 12 hours and that this formulation isas effective as dosing every 6
hours with the same amount of immediate release acetaminophen. In
addition, the time to maximum analgesic effect, following administration of
the sustained release formulation is similar to immediate release. The
pharmacokinetics reported for their formulation indicatea more rapid release
rate then the sustained release formulation that we reported here. Under
very similar experimental conditions, Nielsen et al. (35) reports that a
formulation which releases acetaminophen at rates nearly identicalto rates
reported here, does not produce significant analgesia when comparedto
placebo. In the same study, an equal dose of acetaminophen formulatedas an
immediate release preparation does produce significant analgesia, though
peak blood concentrations of the two formulationsare very similar. This60
observation implies that rate of input may determine not only the time of
onset of analgesia, but may also determine if significant efficacy is achieved.
The results obtained in this study suggest that fevermay be controlled
in an acutely ill pediatric population by dosing with the sustained release
suspension. Immediate release drug may be included with the sustained
release drug in this dosage form. The feverresponse indicates that fever is
significantly reduced for a period of 12 hours andmay be particularly useful
for fever control during the night when parentsmay find repeated dosing
with an immediate release formulation inconvenient. The formulation
strategy employed here may also be applied to other drugs that require large
doses, have a bitter taste, and are used in populations that find traditional
dosage forms difficult to swallow.61
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CHAPTER III
EXPECTED BIOAVAILABILITY OF KCL SUSTAINED RELEASE DOSAGE
FORMS COMPUTED BY NUMERICAL SIMULATION
ABSTRACT
The use of in vitro dissolution to predict bioequivalence of formulations
that differ with respect to in vitro release rate and in vivo absorptionrate is valid
if the mathematical relationship between in vitro release rate and in vivo
absorption is known. An experimental dosage formwas compared to a
marketed standard for in vitro dissolution rate and bioavailability in 27 human
subjects. The following steps were used to describea range of in vitro
dissolution profiles associated with bioequivalence: 1) Estimation ofapparent
whole body elimination rate of K+ following dosage form administration. 2)
Deconvolution of mean urinary excretion rate to estimate in vivo absorption
rate 3) Relationship of in vivo absorption rate with in vitro dissolution rate 4)
Computer simulation of expected mean urinary excretion rate profiles
following administration of dosage forms with different in vitro dissolution
profiles. Formulations are bioequivalent if bioavailabilityparameters are not
significantly different (p<0.1) from bioavailability parameters associatedwith
an innovators formulation. In vitro dissolution profiles associated with
anticipated in vivo bioequivalence were used to describeupper and lower
bounds for % release over time (1 hour 0.2-12.0%, 2 hour 5.4-39.0%, 4 hour
61.2- 80.2%, 8 hour 68.0-89.0%). The modeling method used heremay be
generally applied when an in vitro drug evaluation is demonstratedto be
closely related to an in vivo drug response.65
INTRODUCTION
In vitro dissolution often correlates with andmay be predictive of in vivo
absorption of drugs from both immediate release and sustained release oral
formulations. The use of in vitro dissolution to predict the bioequivalence of
formulations that differ with respect to in vitro dissolution is valid if the
mathematical relationship between in vitro release rate and in vivo absorptionrate
is known. In this research, two sustained release KC1 formulations (generic
sustained release, Biocraft Laboratories, Inc., Patterson, NJ and Micro-K, A. H.
Robbins, Richmond, VA) were compared with respect to in vivo urinary
excretion rate of K+ and in vitro release rate of K+. Comparison of
pharmacokinetic parameters (Cumulative urinary excretion of K+ in 24 hours,
time to peak urinary excretion rate, and peak urinary excretion rate), calculated
for each formulation, indicate no significant difference (p<0.1) inbioavailability
of the two formulations. The productsare also bioequivalent if one defines
bioequivalence as less then 20% difference in each of the threeparameters
identified above. Under currently acceptable statistical comparisons,a 20%
difference is the maximum difference allowed anda smaller difference may be
required for products to be bioequivalent when there isa small variance
associated with the parameters of interest. In vitro cumulative releaserates up to
8 hours are statistically significantly different for thetwo products, however.
The observation that formulations which differ statisticallysignificantly with
respect to in vitro release rate are bioequivalent suggests that similar
formulations, which describe a range of in vitro dissolutionprofiles, may also be
bioequivalent. A range of dissolution profiles, associated withexpected
bioequivalence, may be used to guide development ofnew formulations or as a
basis for making quality control decisions.66
Formulations which differ significantly with respectto in vitro dissolution
profiles can be evaluated for bioavailability in test subjects.Such bioavailability
studies are expensive and time consuming, and extensive evaluationof many
similar formulations in human subjects is not reasonable.Alternatively, in vivo
response (plasma concentration vs time, urinary excretion rate vs. time,or
physiological effect vs. time) may be related mathematicallyto in vitro
dissolution rates. In this study the mathematical relationship identifiedis used
to simulate an expected in vivo response after administration ofa formulation
that releases drug at rates different from the reference formulationin vitro.
Expected bioavailability parameters associated with simulated dataare
compared to the reference formulation, anda range of in vitro dissolution profiles
associated with bioequivalence can be described. The validity ofpredictions
made by the mathematical model is dependenton several assumptions:
1) Rate of absorption of drug from the gastrointestinaltract is dosage
form limited, i.e. dependentupon release from the product.
2) Changes in rate of absorption from the gastrointestinaltract are
associated with a concomitant change in in vivoresponse. In the case of
K+, a concomitant increase in urinary excretionrate is assumed to occur in
response to increased absorption of K+ from the gastrointestinal tract.
3) An apperent whole body eliminationrate of drug, after absorption of
drug from the gastrointestinal tract is complete, isestimable.
n
4) The pharmacokinetics of the drugare linear, i.e. C(t) =A,e-ku` and
,.1
that the property of superposition is applicable, andthat the concentration
of drug in plasma is linearly relatedto the observed in vivo response
(mean urinary excretion rate).67
The application of these assumptions toan observed in vivo response measured
over time provides a basis for comparison of in vitro dissolution to in vivo
absorption.
The mathematical relationship used herein tocompare in vitro dissolution
to in vivo absorption is:
Equation 1 F (t) =[Cumulative % absorbed, in vivo(t)]
[Cumulative % released, in vitro(t)]
Where Fvr(t) is the estimated fraction of drug absorbed in vivoat a given time
relative to drug dissolved in vitro at thesame time. Known mean urinary
excretion rate data from two sustained release KC1 productswere used to
estimate the rate of K+ absorption in vivo, and % K+ absorbedin vivo. The
fraction of drug absorbed in vivo ata given time relative to drug dissolved in vitro
at the same time function (Fvr(t)) can then be used to simulatecumulative %
absorbed, in vivo. This relationship is described by thefollowing equation:
Equation 2
Simulated cumulative %
= F (t)
Simulated % drugl
Labsorbed in vivo(t)] r*[releasedin vitro(t)
r
The simulated rate of drug absorptioncan then be used to estimate the expected
in vivo response. Bioavailability parameters expectedafter administration of
dosage forms that have different in vitro dissolutionrates also can be estimated
and compared for bioequivalence to the referenceformulation (Micro-K). The
relationships expressed in the preceding equationsare simple, however
description of in vivo absorptionprocesses are mathematically complex.The68
functionally complex description of in vivo absorption imposesan important
limitation on how in vitro dissolution rate must be described.
An analytical deconvolution method (1) was applied to estimaterate of in
vivo absorption of K+ from the gastrointestinal tract frommean urinary excretion
rate data. In vivo absorption rate determined by deconvolution is mathematically
complex and continuous, hence the relationship between in vitro dissolution and
in vivo absorption will also be continuous and complex. The mathematical
properties of the in vivo absorption function, complexity and continuity, impose
the requirement that in vitro dissolution data must be described bya continuous
function. Thus, after utilizing deconvolution to obtainan in vivo absorption
function, then the Weibull model, an empirical relationship that has been usedto
describe cumulative % release in vitro, (2,3,4)was selected in this research as a
useful approach to approximate in vitro dissolutionas a continuous function:
Equation 3
-(L)fi F, =F 1 e
Where Ft is the cumulative release in %, Foc, is the cumulative% release at time
infinity, ti is a time scaling parameter, and p isa parameter associated with
curvature of the release rate profile. It is anticipated that other models which
closely approximate dissolution data would be equally useful.In fact, a simple
zero-order dissolution model is also evaluated hereinto define extreme linear
release boundaries of drug release patterns (See results and discussionfor full
description.). A great many stochastic and empirical models have beenproposed
and used to describe dissolution data. Unfortunately,none has been found69
which consistently describes drug release from dosage forms,especially
sustained release products. The Weibull model given in equation 3may be used
both to 'fit' experimental data and to simulate dissolution data.
Simulated in vitro dissolution ratemay be applied through equation 2 to
produce a simulated rate of in vivo absorption. From the simulatedabsorption
rate, a corresponding mean urinary excretion over time profilemay be
generated. Simulated urinary excretion rate profilesmay be compared to the
reference formulation for bioequivalence. Arange of simulated dissolution
profiles associated with expected bioequivalencemay be used as a guide for
dosage form development and/or qualityassurance standards.70
MATERIALS AND METHODS
Bioavailability study
The bioavailability study was designed to determine therate, extent and
variability of absorption and urinary excretion of two potassium chloride
formulations (generic sustained release, Biocraft Laboratories, Inc.,Patterson, NJ
and Micro-K, A. H. Robbins, Richmond, VA) following randomized,equivalent,
repeated doses of 8 sustained release 10 mEq potassium chloride capsules.The
design was open, non-blinded, random, repeated-dose, two-waycross over
design carried out from August 15 to August 30, 1989,at the bioavailability
center of Ian W. French and Associates Limited, Scarborough, Ontario, Canada.
27 normal, healthy, adult male volunteers, who provided informedconsent, were
institutionalized and placed on a standard diet containing 100 mEqpotassium,
340 mEq sodium, 3700 calories and 5200 ml fluidper day. All subjects were
maintained on this diet during the period of the study. Each subjectwas
randomly assigned to receive either Generic sustained releaseor Micro-K
formulation (8, 10 mEq capsules at 7 AM with 400 ml of water)and after a two
day period of washout each subjectwas administered the formulation they did
not receive initially. After a seven day washout, the studywas repeated, except
that subjects received the reverse order of formulations.Urine was collected for
a period of 48 hours post dosing and assayed for potassium by atomic absorption
(IWF Research Laboratories, Mississauga, Ontario, Canada).Baseline urinary
excretion of potassium was determined duringa two day period, three days after
institutionalization. Only mean data, corrected for baseline, fromthe first series
of drug administration was used in subsequent dataanalysis presented herein.71
In vitro dissolution
In vitro dissolution (USP XXI, basket method)was performed on 12
capsules per study lot. Dissolution media consisted of 900 ml of simulated
gastric fluid (without enzymes) for hours 0-1, then 900 ml ofa modified
simulated intestinal fluid (without enzymes anda phosphate buffer not
containing potassium) for hours 1-8, all at 37 Co. Sampleswere collected for
assay of potassium at 1, 4, and 8 hours.
Data Analysis
Steps taken in the analysis fall into three broad categories: 1) Estimation
of observed in vivo absorption rate (deconvolution) and estimation ofparameters
associated with observed in vitro dissolution data i.e. Weibullparameters. 2)
Simulation of in vitro dissolution profiles and urinary excretionrates. 3)
Comparison of simulated urinary excretion ratevs. time curves for
bioequivalence.
Parameters associated with the Weibull model of cumulative % releasein
vitro were estimated using procedure NUN of SAS (Statistical AnalysisSoftware,
Cary, NC).Analytical deconvolution of observedmean urinary excretion rate
was performed with PCDCON (Dr. William Gillespie, University of Texas at
Austin) on an IBM compatible PC. Aprogram was written to perform all
simulation steps and calculate bioavailability parameters. Theprogram was
written in THINK PASCAL 4.0 (Macintosh).
Estimation
1) Estimation of apparent whole body eliminationrate, post absorption.
A linear regression estimate of slope of In of observedmean urinary
excretion rate at 7, 10, 14 and 20 hourswas made for each product. The 772
hour time point was included as absorption isover 90% complete at 7
hours (shown in results section). Rate of change in urinary excretionrate,
post absorption is expressed as:
Urinary excretion rate(t) = A * e-k61
where Kel is the apparent whole body eliminationrate constant estimated
by linear regression. A is a term estimated by the regression fort=7 hours.
2) Deconvolution of observedmean urinary excretion rate.
Deconvolution analysis requires the apparent whole body eliminationrate
constant obtained above and observed mean urinary excretion rate data.
The deconvolution analysis producesa function that describes cumulative
urinary excretion rate over time. Cumulativemean urinary excretion rate
has no physiological meaning, however this function isassumed to be
linearly related to cumulative amount of K+ absorbedover time.
3) Normalization of cumulativemean urinary excretion rate to 100% at
maximum cumulative mean urinary excretionrate. Normalization to
100% results from dividing each cumulative excretionrate by the
maximum cumulative urinary excretionrate calculated in step two and
enables expression of the relationship in equation1:
F (t) =[Cumulative % absorbed, in vivo(t)]
[Cumulative % released, in vitro(t)]73
Recall that cumulative urinary excretion rate is directly relatedto
cumulative amount of K+ absorbed from the gastrointestinaltract.
4) Estimation of Weibull model parameters associatedwith observed in
vitro cumulative release % (equation 3). The variables 13 andt are
obtained using SAS procedure NUN (Statistical Analysis Software,Cary,
NC) to obtain the best fit of known dissolution datato the equation:
Ft = F..
5) Computation of elements of equation 1:
F.(t)=[Cumulative % absorbed, in vivo(t)]
[Cumulative % released, in vitro(t)]
This equation uses the results of steps 3) and 4) aboveapplied to data from
the known dissolution and bioavailability study.
6) Simulation of in vitro dissolution profile usingequation 3. This is
accomplished by varying parameters (3,t , and Fee within limits described
in the text.
7) Simulation of in vivo absorptionrate. This step utilizes the results of
step 5 (relationship between in vivo absorption and in vitrodissolution)
and step 6 (in vitro dissolution simulation byvariation of Weibull
parameters) and applying these results throughequation 2:74
Simulated cumulative %
Labsorbed in vivo(t)
r
= Fe(t)*[
Simulated % drug]
released in vitro(t)
Recall that change in rate of absorption of K+ from the gastrointestinal
tract is directly related to change in rate of urinary excretion. Thus,
cumulative % excretion rate, a term that arises from deconvolution of
urinary excretion rate data and has no physiological meaning, is directly
related to cumulative % absorbed in vivo.
8) Simulation of mean urinary excretion rateover time profile. The
estimated in vivo drug absorption rate, from step 7, is approximated by
assuming a series of sequential 0 order input functionsevery 30 minutes
(results from assumptions inherent in the complex mathematics of
deconvolution). The apparent whole body elimination rate estimated in
step 1 is used in this model. For time during which an input ioccurs,
change in urinary excretion rate is given by equation 5 (5):
Equation 5 U,(t)=(17,-1-)* (1ekd(`
Where ki is the input rate, tbegin,i is the time that the ith input begins,and kel is
the apparent whole body elimination rate constant determinedin step 1). After
the ith infusion has ended, change in urinary excretionrate is expressed as
equation 6 (5):
Equation 6U,(t)=()*(1e * e
- kd (t-tbeg,,,)
kei75
Where tend,i is the time that the ith infusion ends.
The contribution of all infusions are summed. Thus the simulatedurinary
excretion rate at time t is:
Equation 7 SimUrate(t) U; (t)
.,
The simulation software allows input tooccur for up to 12 hours. If the rate of
change in simulated in vivo absorption becomesvery small (.005% of previous
input) or negative, the input rate is set to 0. Thismeans that the simulated
cumulative urinary excretion rate profile produced instep 7) is approximated by
23 sequential, 0 order inputs from the gastrointestinaltract for these products.
Bioavailability parameters associated with the simulatedmean urinary
excretion rate vs time profile are calculated and compared with the
bioequivalence intervals associated with the reference formulation(Micro-K).76
RESULTS AND DISCUSSION
Table 1 shows mean cumulative urinary excretion of K+ in the urine
following administration of 80 mEq of generic sustained release product, and
mean cumulative excretion of K+ following administration of 80 mEq of Micro-K,
to 27 subjects in a cross-over study design. Only the first administration is
considered for analysis. Mean values in table 1are corrected for baseline
excretion of K+ in the urine and show that most excretion of K+ absorbedoccurs
within 24 hours, but that some excretion from the dosage formsoccurs during
the period of 24 to 48 hours. Table 2 showsmean urinary excretion rates for the
period of 24 hours. Mean urinary excretion rates after 24 hourswere small and
varied in a random fashion, and were not included in subsequentanalysis. FDA,
Division of Bioequivalence guidelines for slow release KC1 productsrecommends
comparison of cumulative urinary excretion from 0 through 24 hours. Table3
describes the statistical confidence intervals (p<0.1) associated with
bioavailability parameters of Micro-K while Table 4 showsupper and lower
bounds associated with bioequivalence to Micro-K, assuming± 20% variation in
each parameter is acceptable.
The peak urinary excretion rate obtained from averagingthe excretion
rates at each time for the Micro-K product (see table 2 and figure 5,5.38 mEq/hr.
at 7 hours) was used as a bioequivalence reference value for thisparameter.
Note that this value is significantly less than the value obtainedif mean of
individuals peak values are used (generic sustained releasepeak rate 7.56
mEq/hr., Micro-K peak rate 7.82 mEq/hr., Table 5). Thisdifference is expected
since the former method of averaging individual timepoint data results in
attenuation of the data relative to averaging the peak valuesfor each individual.
Table 5 shows that peak excretion rates for most individualsoccur at 5 or 7 hoursTable III.1Cumulative urinary excretion of K. In mEq following 80 mEq dose, first administration.
Standard deviations in parenthesis.
Time (hours)I Generic SR Micro-K
1 0.31(1.82) -0.31(1.62)
2 1.60(2.37) 1.29(3.10)
4 8.58(4.91) 8.15(3.27)
6 18.66(7.22) 18.78(7.44)
8 31.24(10.32) 29.53(9.48)
12 46.49(10.93) 46.14(11.48)
16 53.26(10.75) 52.93(11.87)
24 56.55(11.35) 55.34(11.48)
36 64.40(18.25) 63.57(18.72)
48 65.55(22.38) 63.95(20.06)Table 111.2Mean urinary excretion rate (mEq/hr.) at midpoint of
collection intervala. Standard errorb in parenthesis.
Time (hours)a Generic SR Micro-K
0.5 0.31(1.8) 0(1.62)
1.5 1.29(2.1) 1.29(2.2)
3 3.49(1.4) 3.43(1.3)
5 5.04(1.7) 5.32(1.6)
7 6.29(2.1) 5.38(2.0)
10 3.81(1.1) 4.15(1.1)
14 1.69(1.2) 1.70(1.2)
20 0.41(0.6) 0.30(0.6)
a Time in hours represents the midpoint of time between collection
intervals (see table 1).
Mean urinary excretion rate(t)=[Cumulative(ti+1)-Cumulative(ti)]/(hours ininterval).
b Standarderror for table 2 is the standard deviation for difference of mean
cumulative urinary excretion reported in table 1 divided by the number of
hours in the cumulative interval i.e. SEM=(Ai(s,2
ss2+1))/ (Hours in interval)Table 111.3Bioavailability parameters (lower andupper bounds of confidence
interval) and associated statistics.
Parameter Micro-K
mean
Generic
SR mean
SDlower
bounda
upper
bounda
Time to peak 6.74 6.22 2.35 5.65 7.83
Peak rate 5.38 6.29 2.58 4.16 6.60
Cumulative excreted 24
hr. 55.34 56.5511.4850.01 60.67
a Confidence intervals based on. n=27, with Micro-K dataas the 'standard'.
Upper, Lower bound = mean + [1.70 * (SD * V2 / n)1,where 1.70 is
critical t value for a two-sided student t test where p<.1, df=26.Table 111.4Bioavailability parameters and statistics associated with bioequivalence
(lower and upper bounds of confidence interval), assuming +20% variationis
allowed in each parameter and Micro-K is the 'standard'.
Parameter Micro-K
mean
Generic SR lower
mean bound
upper
bound
Time to peak 6.74 6.22 5.39 8.09
Peak rate 5.38 6.29 4.30 6.46
Cumulative excreted 24
hr.
55.34 56.55 44.27 66.41Table 111.5Mean peak urinary excretion rate of K +, of individuals.
Number of individuals that peaked at that time given in parenthesis.
Time of peak
excretion rate (hour)
Generic SR, mean peak
excretion rate (mEq/hr.)
MicroK, mean peak
excretion rate (mEq/hr.)
3 5.01(3) 7.83(1)
5 7.81(8) 7.81(11)
7 8.04(15) 8.54(10)
10 (0) 7.24(4)
14 5.85(1) 3.67(1)82
for both formulations and that these valuesare significantly higher then the
mean average values reported in table 2. Cumulative urinary excretion of K+ in
24 hours and time to peak urinary excretion rate reference valuesare the means
of individuals observed values for theseparameters.
Figure 1 shows the in vitro dissolution profiles of Micro-K and generic
sustained release products evaluated in the bioavailability study. The
dissolution profiles differ significantly (p<0.0001) at 1 hour and 4 hours,and are
similar at time points 2 and 8 hours. Weibull model estimates ofindividual in
vitro dissolution data points are within 1 standard deviation (6 replicates for
dissolution) at all times. The Weibull model predictsno significant release of K+
occurs from the generic sustained release product after 8 hours, but Micro-K is
predicted to continue to release K+ at a significant rate for nearly 12 hours.
Although the Weibull model predictioncan be useful, it is important to point out
here that the model is correct in estimating total K+ release fromthe generic
sustained release product at 8 hours but underestimates the actualamount
dissolved at time infinity. The remaining 14% of K+ will bereleased after 8
hours of dissolution, and the error in estimation results fromthe curvature
assigned by the model in order to closely fit thevery few (4) data points.
Unfortunately there are no dissolution data beyond 8 hours,and only one point
between 2 and 8 hours. Dissolution does continueto 100% release for the generic
sustained release product since cumulative K+ excretionessentially equals the
Micro-K product at both 24 and 48 hours (Table 1).
Estimation of rate of absorption in vivo requires thatapparent whole body
elimination rate is estimable.Since subjects dietary regimen includesan
amount of potassium sufficient to meet the bodies needs, thepotassium absorbed
from the sustained release dosage forms is rapidlyeliminated. Thus, the
apparent whole body elimination rate referred to herein is therate at which100
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potassium is eliminated by the body when dietary intakeis sufficient to maintain
whole body stores at equilibrium and additionalpotassium has been
administered in the sustained release dosage form. Theslope associated with a
least squares fit of log transformedmean urinary excretion rate versus time data
at 7, 10, 14 and 20 (Table 2) hourswas used to estimate the apparent whole body
elimination rate constant (Kel) post absorption (hereaftercalled elimination rate
constant, Kel). An elimination rate of .2125 hr-1 and .2283 hr-1were calculated
for generic sustained release and Micro-Krespectively and are in good
agreement with values reported in other studies (6,7). The relativelysimilar
estimates for whole body elimination rateconstants are expected since
elimination rate should not dependon which formulation is administered.
However, the estimate of in vivo percent absorbed,provided by analytical
deconvolution, indicates that 15% and 8% of theabsorbed dose will be absorbed
during 7 though 11 hours post dosing withMicro-K and generic sustained
release formulations respectively. Thus, estimatesof whole body elimination
rate, based in part on observed mean urinary excretionrates at 7 and 10 hours,
are somewhat confounded by concomitant absorption ofpotassium from the
gastrointestinal tract. An alternative estimate ofwhole body elimination rate, for
each formulation, usingmean urinary excretion rate at 10,14 and 20 hours for
estimation, provided whole body eliminationrate constant estimates that differ
by 15% (0.2238 hr-1 vs 0.2625 hr-1 forgeneric sustained release and Micro-K
respectively).Differences in estimated Kel of K+, in previousstudies using a
crossover design, may vary as much as reported here (6),however when a large
number of post absorption time pointsare available, estimates of Kel for
different treatments are similar (7). Thus,despite the lack of confounding by
concomitant absorption during the period of10 through 20 hours, whole body
elimination rate constant estimates basedon this period may be less reliable then85
estimates based on the period of 7 though 20 hours since the statistical
uncertainties associated with observed low mean urinary excretionat 14 and 20
hours may be large and may provide misleading estimates of wholebody
elimination rate constant. As an alternative,a reference value for Kel from the
literature could be applied to analysis of both generic sustained releaseand
Micro-K mean urinary excretion data. This may beas meaningful as estimated
Kel's. However, since Kel varies with dietary regimen,use of a literature value of
Kel to be representative of the bioavailability study examined hereis also
uncertain. For these reasons, whole body elimination rateconstant was
estimated from the last four observed mean urinary excretionrates.
Figure 2 is the outcome of deconvolution analysis, using the whole body
elimination rate constants chosen above, which mathematicallyconverts the
mean urinary excretion rate vs time data into a cumulative area over time
relationship. The y-axis units in figure 2are real mathematically but the labeled
values have no directly useful physiological meaning. Figure2 shows the
"cumulative mean urinary excretion rate" (y axis) requiredto produce the
experimentally observed urinary excretion rates. Basedon deconvolution
assumptions, cumulative mean urinary excretionrate is directly related to
cumulative amount of K+ absorbed. Figure 2 shows that K+absorption from the
gastrointestinal tract for the generic sustained release productremains nearly
constant for 8 hours, and then plateaus, i.e. the cumulativearea for mean urinary
excretion rate (y-axis) reaches an asymptote. Input fromMicro-K is nearly
constant from 1 to 4 hours and then slows gradually until absorptionends at 11
hours.
Deconvolution results shown in figure 2were normalized so that at some
time, all absorption of K+ which is bioavailable, is100% complete. This does not
require that bioavailability will be 100%, but only thatthere is a time at which allal9
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drug that will be absorbed has been absorbed, andno further absorption occurs
after that time. 100% completion of absorptionoccurs at 8 and 11 hours and has
values of 12.4 and 13.3 mEq/hr. for generic sustained release and Micro-K
formulations respectively. The normalized percent cumulative urinaryexcretion
rate can be equated to the percent drug absorbed in vivo,and then be compared
directly with observed in vitro cumulative percent release (figure 3).
Figure 3 shows that amount of K+ released in vitro isgreater then
absorption of K+ in vivo at the same time points for all timesexcept 8 hours
when the amount released in vitro is approximately equalto the amount
absorbed in vivo. The heavy solid line describes the relationship that would be
observed if in vitro dissolution rate exactly predicted in vivo absorptionrate. The
relationship between in vitro dissolution and in vivo absorption is continuously
described by application of equation 2. This resultcan be seen in figure 4.
Figure 4 shows that for the generic sustained release product, in vitro
dissolution cumulative % release closely approximates the in vivo %absorption at
0.5 hours (value of fraction=1.2), then declines steadilyto a value of 0.5 at 2
hours and then increases gradually toassume a final value of 1.15 at 8 hours. By
contrast, the in vitro-in vivo relationship associated with the Micro-K product
begins at 0 and increases steadily reachingan asymptote of 1.0 at 8 hours.
Figure 4 shows for example, that for the generic sustainedrelease product, in vivo
absorption at 2 hours is predicted to be 52% of the in vitrodissolution at 2 hours.
For the generic sustained release formulation during the periodprior to 0.5
hours, the fraction described in equation 2 isvery large. These values are
artifacts that arise from the division ofa relatively large number (% absorbed as
determined by deconvolution) by a relatively small number (%release described
by the Weibull dissolution model). These large valueswere replaced by a simple
linear interpolation of the value from 0 to 0.5 hours. Therelationships depicted100
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in figure 4 and mathematically described by equation 2may now be used to
simulate in vivo absorption rates from simulated dissolution profiles.The
inherent assumption, of course, is that while different lots of product fromthe
same manufacturer may have different dissolution profiles, the in vivo-in vitro
relationship is still described by the function plotted in figure 4. These
absorption rates are then used to simulatemean urinary excretion rate vs time
profiles.
The software developed generatesa simulated mean urinary excretion
function (excretion rate vs time profile) that describes the expectedmean urinary
excretion rate at intervals of 6 minutes fora period of 24 hours. The program
also records the peak urinary excretion rate and timeto peak rate. Cumulative
urinary excretion rate was computed as thearea under the excretion rate vs. time
profile calculated as the sum of adjacent simulated urinaryexcretion rates
divided by two and multiplied by 6 minutes for the entire24 hour period
(trapezoidal rule). Prior to application of the softwareto simulated in vitro
dissolution profiles, the precision of the modelwas tested by comparing known
dissolution data and simulated urinary excretionrates with observed urinary
excretion rate data from the bioavailability study. The resultsof these
applications are seen in figure 5.
Figure 5 shows that the deconvolution method coupled withthe Weibull
parameters determined by fitting the dissolution data and the newly developed
simulation software very closely describes the observedmean urinary excretion
rate data. Small differences between simulated and observed dataduring the
period of 7 to 20 hours may reflecterrors associated with lack of fit
corresponding to the estimation of whole body eliminationrate constant.
Cumulative urinary excretion of K+ in 24 hours alsoclosely approximated
observed values. For example, predicted total K+ excretedin 24 hours for theVisv,le \\N. 592
generic sustained release product was 56.50 mEq vs observed 56.35 mEq and for
Micro-K predicted total K+ excreted 55.82 mEqvs observed 55.34 mEq (Table 3).
These close fits are expected, of course, since the deconvolution-convolution
methods were developed using exactly the same in vitro dissolution and in vivo
urinary excretion data as are now shown to produce the lines of good fit in figure
5, i.e., the computer programs and mathematical modelsare working correctly.
Description of a range of in vitro dissolution profiles associated with
bioequivalence was achieved by simulating in vitro dissolution profiles by
varying Weibull parameters t (curvature of in vitro dissolution profile) and Fc.,
(maximum release at infinite time) and evaluating the associated urinary
excretion profiles for bioequivalence by comparison to values in table 4. In
addition, whole body elimination rate constantwas also varied (.19-.22 hr-1) to
evaluate the effect of errors in estimation of whole body eliminationrate
constant. Approximately 1000 simulations were performed to evaluate the
parameter space associated with bioequivalence. Figure 6 shows the extreme
limits of dissolution profiles estimated to be associated with bioequivalencewith
the Micro-K product. The generic sustained release product evaluated for
bioavailability falls within limits at all times. Theupper and lower limits for
acceptable dissolution, at times 1,2,4, and 8 hours for the Weibull dissolution
model is found in table 6. Figure 7 shows the expectedmean in vivo urinary
excretion rates which correspond to dissolution profiles shown in figure5.Note
that while the curves in figure 7 are quite different, theextremes differ by less
then 20% in all three bioavailability parameters of interest whencompared to the
values observed.
A linear model to simulate zero order in vitro dissolutionwas also applied.
Linear models of in vitro dissolution (i.e. dissolution describedby a 0 order
process with 100% release) were unable to describe any mean in vivo urinary90
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lower upper
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8 68.0 89.0
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excretion rate simulations that are associated with bioequivalenceto Micro-K.
This shows that formulation of a product that producesa zero order release in
vitro and is also bioequivalent is a difficult task. This is not surprising sincethe
release rate of Micro-K is not zero order. The effect of variation of wholebody
elimination rate constant was insignificant through thenarrow range
investigated (.19-.22 hr-1).
The modeling approach used herein is not limited to analysis of K+
sustained release products, but is applicable toany drug that satisfies model
assumptions. For K+, the assertion that necessary model assumptionsare
fulfilled is supported by the pharmacokinetics of K+as reported in the literature.
The assumption that absorption of K+ is dosage form limited is supportedby the
observation that administration of oral solutions producesa nearly instantaneous
increase in plasma concentration of K+ (6). Plasma peak concentrations
following administration of an oralsyrup occur within 30 minutes (8). Sustained
release formulations produce rates of absorptionso slow that no discernible
change in plasma concentration mayoccur (5,6). Therefore, the assumption that
rate of absorption from the gastrointestinal tract is associated witha concomitant
change in plasma concentration is apparent with formulations thatdeliver K+
rapidly. However, for sustained release formulations of K+, plasmaappears to
be a poor indicator of rate or extent of K+ absorption since the changeis small
enough not to be statistically different from baseline.Thus, reliable
determination of absorption rate from the gastrointestinaltract and
bioavailability of K+ from sustained release dosage formscannot be made from
plasma vs time data. An appropriate alternativeto plasma concentration vs time
data is urinary excretion rate data.
Use of urinary excretion rate changes to estimate absorptionrate requires
that a mathematical relationship between changes inabsorption rate from the97
gastrointestinal tract and urinary excretion rate is known. Inour analysis we
have assumed that change in rate of absorption of K+from the gastrointestinal
tract produces a parallel increase in urinary excretionrate (eq. 1). Rabinowitz, et
al., (9) reported that during the intravenous infusion of K+to ewes, changes in
urinary excretion rate paralleled the infusionrate. Three different infusion rates
were examined and in each case urinary excretion ratewas the same fraction
(-0.3) of infusion rate. When high doses of K+are administered as oral solutions
in man, increase in rate of urinary excretion parallels theincrease of K+ in plasma
(10). Unfortunately the rate of IV infusion reportedby Rabinowitz et al. is an
order of magnitude greater then what has been observed forabsorption rate in
our research. Thus the assumption of a simple linear relationship between
urinary excretion rate during periods of slow absorption of K+from a sustained
release dosage form must be made with caution.
The relationship between in vivo % absorbed and invitro % released is
quite different (Figure 4) for the generic sustainedrelease and Micro-K products
evaluated in the bioavailability study. Since both formulationswere evaluated in
the same in vitro dissolution media, differencesmust exist in how each dosage
form interacts with luminal contentsor surface of the gastrointestinal tract.
Specific interactions may include, butare not limited too, response of polymers
to change in pH, bile salts or other surface activeagents. Shape and size of the
dosage form may also effect transit time throughthe gastrointestinal tract and
may contribute to the differences observed in the in vitro-in vivo relationshipof
the two formulations. Because of the differencein the in vitro-in vivo relationship
of the two formulations, the model describedhere is best applied to formulations
that have similar physical-chemical properties,basic formulations, and
processing variables. The use of in vitro dissolutionmedia that contains
surfactants, or enzymes may identify thesource of difference in vitro-in vivo98
relationship between the two formulations. Other limitations have also been
presented in the application of the model.
The model accurately predicts mean cumulative urinary excretion in 24
hours, time to peak urinary excretion rate, and peak urinary excretionrate in rate
averaged data but significantly underestimates theaverage of peak urinary
excretion rates of individuals. The model when applied tomean data does not
detect this behavior, however the model can also be applied to individuals
within the study population. Table 5 shows that peak urinary excretionrates of
individuals are much higher then the mean rates given in table 2. Statistical
methods may be applied to build a more complex model that would correctly
predict the mean of peak excretion rates.
In order to identify sub-populations with peak characteristics attributable
solely to absorption rate, the complexity of the result obtained by numerical
deconvolution must be reduced so that statistical methodsmay be applied.
Calculation of the first moment of cumulative excretionrate with respect to time
(analogous to mean absorption time, MAT, that is appliedto plasma vs time
data), may reduce the complexity of individual absorptionrate data obtained
from individuals. This reduction in complexitymay provide the means for
identification of sub-populations and thereby enable the construction ofa model
which predicts the high mean peak excretion rate observed in individualdata.
The use of statistical moments to reduce the complexity of deconvolution
estimates of rates of absorption of drugs from the gastrointestinaltract, and the
correlation of these moments to bioavailabilityparameters has been reported
(2,11).
Estimation of rate of absorption from the gastrointestinaltract is probably
the single greatest source of error present in this analysis. Theexplicit
deconvolution method used here was chosen for severalreasons. We assumed99
from the outset that absorption rate from the gastrointestinal tractwas not likely
to be described by a simple first or zero order process. This assumption is
consistent with the problems commonly associated with mathematical modeling
of the pharmacokinetics of sustained release dosage forms. In fact, modeling
mean urinary excretion rate with a single 0 order or first order input was
examined prior to use of deconvolution. While a single 0 order input did
produce a fair estimate (data not shown), it is our belief that deconvolution
produces a more precise estimate of absorption rate and thus ismore likely to be
useful in generating meaningful simulations.100
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